I 
117TH CONGRESS 
2D SESSION 
H. R. 7640 
To amend the Orphan Drug Act to reauthorize a program of grants and 
contracts for the development of drugs for rare diseases and conditions 
(commonly referred to as ‘‘orphan drugs’’). 
IN THE HOUSE OF REPRESENTATIVES 
MAY 3, 2022 
Mr. BILIRAKIS (for himself and Mr. BUTTERFIELD) introduced the following 
bill; which was referred to the Committee on Energy and Commerce 
A BILL 
To amend the Orphan Drug Act to reauthorize a program 
of grants and contracts for the development of drugs 
for rare diseases and conditions (commonly referred to 
as ‘‘orphan drugs’’). 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
VerDate Sep 11 2014 
22:00 May 03, 2022
Jkt 029200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H7640.IH
H7640
kjohnson on DSK79L0C42PROD with BILLS
2 
•HR 7640 IH
SECTION 1. REAUTHORIZATION OF GRANTS AND CON-
1
TRACTS FOR DEVELOPMENT OF ORPHAN 
2
DRUGS. 
3
Section 5(c) of the Orphan Drug Act (21 U.S.C. 
4
360ee(c)) is amended by striking ‘‘2018 through 2022’’ 
5
and inserting ‘‘2023 through 2027’’. 
6
Æ 
VerDate Sep 11 2014 
22:00 May 03, 2022
Jkt 029200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6301
E:\BILLS\H7640.IH
H7640
kjohnson on DSK79L0C42PROD with BILLS
